Company profile
ALZAMEND NEURO, INC.
NASDAQ:ALZNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LATOZINEMAB | phase1_2 | — | 8 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06921590 | phase1 | completed | 2025-05-09 | 2025-12-15 | Alzamend Neuro, Inc. | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects |
| NCT07540338 | phase1_2 | recruiting | 2026-05-11 | 2026-12-01 | Alzamend Neuro, Inc. | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder |
| NCT05363293 | phase1_2 | completed | 2022-05-04 | 2023-04-14 | Alzamend Neuro, Inc. | Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects |
| NCT05834296 | phase1_2 | active_not_recruiting | 2023-07-05 | 2028-03-03 | Alzamend Neuro, Inc. | Study in Subjects With Mild-to-Moderate Alzheimer's Dementia |
FDA applications (0)
No records yet.